- Home
- » Tags
- » Regorafenib
Top View
- Multicenter Retrospective Analysis of the Safety and Efficacy of Regorafenib After Progression on Sorafenib in Korean Patients with Hepatocellular Carcinoma
- Survival in Advanced GIST Has Improved Over Time and Correlates
- For Health Professionals Who Care for Cancer Patients
- Tasigna® (Nilotinib)
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Regorafenib > Printer-Friendly PDF
- Clinical Pharmacology Biopharmaceutics Review(S)
- Gastrointestinal Stromal Tumors: What Do We Know Now? Christopher L Corless
- Caresource Prior Authorization Criteria (Updated November, 2018)
- Regorafenib (Stivarga) National Drug Monograph February/March 2013 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll
- Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the Ifng/STAT1 Signaling in Hepatocellular Carcinoma Cells
- Histone Deacetylase Inhibitor Resminostat in Combination with Sorafenib Counteracts Platelet-Mediated Pro-Tumoral Effects In
- Reimbursement Criteria for Frequently Requested Drugs
- Regorafenib (Stivarga) Is an Orally Administered Kinase Inhibitor Acting on Various Membrane-Bound and Intracellular Kinases
- Stivarga, INN-Regorafenib
- Ipsen – MAIC – 19 May 2020
- Targeting HER2 with Trastuzumab Deruxtecan: a Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- How I Treat Chemorefractory Metastatic Colorectal Cancer
- Regorafenib: Drug Information
- Phase I Study of Rapid Alternation Of
- Regorafenib Inhibits Colorectal Tumor Growth Through PUMA-Mediated Apoptosis
- Phase I Study of Rapid Alternation Of
- Stivarga, INN-Regorafenib
- Regorafenib-Avelumab Combination in Patients with Microsatellite Stable
- Overcoming Heterogenity in Imatinib-Resistant Gastrointestinal Stromal Tumor
- Download PDF File
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Tasigna (Nilotinib)
- 205832Orig1s000
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
- Micromanagement of Drug-Resistant Advanced Gastrointestinal Stromal Tumors: Regorafenib—New Ammunition in Battling Exon 17 Mutations
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Regorafenib Approved for Liver Cancer
- Regorafenib Or Cabozantinib in Second Or Subsequent Lines After Sorafenib in Advanced Hepatocellular Carcinoma
- Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine-Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
- Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable Or Metastatic Breast Cancer After Two Or More Anti- HER2 Therapies Confidential Until Published
- Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib MARIOS PAPADIMITRIOU and CHRISTOS A
- Caresource Prior Authorization Criteria (Updated November, 2019)
- Multikinase-Inhibitor Screening in Drug-Resistant Osteosarcoma
- Risk Assessment and Risk Mitigation Review(S)
- Availability of Evidence of Benefits on Overall Survival and Quality of Life Of
- STIVARGA (Regorafenib) Tablets, Oral • Cardiac Ischemia and Infarction: Withhold Stivarga for New Or Acute Cardiac Initial U.S
- Prior Authorization Criteria
- Approval Package For
- TITLE: a Phase I/ II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
- Stivarga (Regorafenib)
- Update on Molecular Genetics of Gastrointestinal Stromal Tumors
- Evolution in Treatment for Esophageal and Gastric Cancer
- Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: a Case Report
- Clinical Value of Next Generation Sequencing of Plasma Cell-Free
- Anti-Tumoral Activity of Single and Combined Regorafenib Treatments In
- Nintedanib (OFEV, BIBF 1120)